Cihan Yurdaydin Selected Research

Cihan Yurdaydin Research Topics

Disease

22	Chronic Hepatitis B 11/2020 - 09/2004
19	Infections 01/2022 - 10/2002
18	Fibrosis (Cirrhosis) 06/2021 - 10/2002
14	Hepatitis D 01/2022 - 08/2002
13	Liver Diseases (Liver Disease) 06/2021 - 08/2002
12	Chronic Hepatitis D 01/2022 - 08/2002
11	Hepatocellular Carcinoma (Hepatoma) 11/2020 - 07/2005
10	Hepatitis B 01/2022 - 08/2002
7	Chronic Hepatitis (Chronic Active Hepatitis) 01/2021 - 10/2002
3	Liver Neoplasms (Liver Cancer) 01/2021 - 10/2012
3	Virus Diseases (Viral Diseases) 01/2019 - 07/2003
3	Hepatitis 09/2012 - 03/2005
2	Acute Liver Failure (Fulminant Hepatic Failure) 01/2021 - 07/2010
2	Coinfection 09/2020 - 08/2015
2	Liver Failure 02/2012 - 07/2003
2	Liver Cirrhosis (Hepatic Cirrhosis) 02/2012 - 06/2007
2	Cholestasis 02/2006 - 04/2005
2	Fatigue 04/2005 - 09/2004
1	COVID-19 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	End Stage Liver Disease 12/2020
1	Hepatolenticular Degeneration (Wilson's Disease) 01/2019
1	Superinfection 08/2015
1	Massive Hepatic Necrosis 08/2015
1	Disease Progression 01/2014
1	Chronic Hepatitis C 06/2011
1	Hepatitis C 04/2011
1	Jaundice (Icterus) 07/2010
1	Persistent Infection 09/2009
1	Alcoholism (Alcohol Abuse) 09/2009
1	Viremia 06/2006
1	Non-alcoholic Fatty Liver Disease 11/2005
1	Obesity 11/2005
1	Type 2 Diabetes Mellitus (MODY) 11/2005
1	Fatty Liver 11/2005

Drug/Important Bio-Agent (IBA)

16	InterferonsIBA 01/2022 - 08/2002
16	Lamivudine (Epivir)FDA Link 01/2017 - 08/2002
12	Hepatitis B e AntigensIBA 01/2017 - 07/2003
11	RNA (Ribonucleic Acid)IBA 10/2021 - 08/2002
11	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2021 - 07/2003
10	Antiviral Agents (Antivirals)IBA 01/2021 - 06/2006
10	entecavir FDA Link 11/2020 - 06/2006
8	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 07/2003
8	Tenofovir (Viread)FDA Link 11/2020 - 01/2014
5	Interferon-alpha (Interferon Alfa)IBA 01/2022 - 07/2003
5	Pharmaceutical PreparationsIBA 02/2013 - 07/2010
4	lonafarnib (SCH 66336)IBA 01/2022 - 10/2015
4	AlbuminsIBA 06/2021 - 06/2011
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 06/2011
3	AntigensIBA 01/2022 - 07/2003
3	peginterferon alfa-2a (Pegasys)FDA Link 01/2019 - 09/2004
3	adefovirIBA 12/2015 - 01/2012
3	Alanine Transaminase (SGPT)IBA 09/2012 - 07/2003
2	Ritonavir (Norvir)FDA Link 01/2022 - 01/2017
2	TransferasesIBA 01/2017 - 06/2011
2	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 04/2011
2	NucleosidesIBA 01/2017 - 08/2002
2	EnzymesIBA 12/2015 - 08/2002
2	Immunoglobulin M (IgM)IBA 01/2014 - 01/2012
2	Proteins (Proteins, Gene)FDA Link 02/2012 - 03/2005
2	PPAR alphaIBA 12/2008 - 11/2005
2	Hepatitis B Core AntigensIBA 06/2006 - 03/2003
2	Serotonin (5 Hydroxytryptamine)IBA 02/2006 - 04/2005
1	Circular DNAIBA 01/2022
1	Virulence Factors (Pathogenicity Factors)IBA 10/2021
1	Transaminases (Aminotransferases)IBA 01/2021
1	CopperIBA 01/2019
1	Emtricitabine (Emtriva)FDA Link 01/2017
1	sofosbuvir drug combination ledipasvirIBA 01/2017
1	nasIBA 01/2017
1	Cholinesterases (Cholinesterase)IBA 01/2017
1	lipoarabinomannan (LAM)IBA 01/2017
1	RacivirIBA 01/2017
1	daclatasvirIBA 01/2017
1	paritaprevirIBA 01/2017
1	ombitasvirIBA 01/2017
1	NucleotidesIBA 01/2017
1	dasabuvirIBA 01/2017
1	SofosbuvirIBA 01/2017
1	clemizoleIBA 02/2013
1	Interferon Type IIBA 01/2012
1	Laminin (Merosin)IBA 06/2011
1	CollagenIBA 06/2011
1	Hyaluronic Acid (Hyaluronan)IBA 06/2011
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 06/2011
1	Collagen Type III (Type III Collagen)IBA 06/2011
1	Telbivudine FDA Link 05/2011
1	AflatoxinsIBA 09/2009
1	Surface Antigens (Surface Antigen)IBA 04/2009
1	Taurine FDA Link 06/2007
1	Hydroxyproline (4 Hydroxyproline)IBA 06/2007
1	adefovir dipivoxil (Hepsera)FDA Link 01/2007
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 06/2006
1	LipidsIBA 11/2005
1	Neurotransmitter Agents (Neurotransmitter)IBA 04/2005

Therapy/Procedure

25	Therapeutics 01/2021 - 08/2002
8	Liver Transplantation 01/2021 - 01/2012
1	Duration of Therapy 01/2018
1	Aftercare (After-Treatment) 12/2015
1	Lasers (Laser) 02/2012